Bristol-Myers Squibb offers $4.5 billion for ImClone

Share this article:

Bristol-Myers Squibb (BMS) has announced an offer of $60 per share, or roughly $4.5 billion, for the acquisition of ImClone. BMS already owns approximately 17% of ImClone's shares.

The proposition represents a 30% premium over ImClone's stock price at close on July 30, according to a company statement. “Bristol-Myers Squibb is the natural partner for ImClone as we possess the knowledge base and resources to advance the company's growth over the long-term, not only with respect to Erbitux, the important cancer therapy we jointly commercialize, but also in terms of developing ImClone's pipeline assets,” said James Cornelius, chairman and CEO of BMS.

BMS and ImClone have worked in collaboration for seven years. Erbitux (cetuximab), a cancer drug, brought in $185 million in the US in 2007, and $1.3 billion worldwide, according to ImClone financial data.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.